PDUFA Old School: Industry Wants User Fees To Get Back To Basics
Calling the current level of industry financial support for new drug reviews "unseemly," Kay Holcombe, a senior policy advisor at Genzyme, says FDA, industry and other stakeholders need to find a way to refocus PDUFA on its original intent - improving efficiency in the drug review process
You may also be interested in...
The biggest changes that came out of the FDA Amendments Act, the last round of Prescription Drug User Fee Act reauthorization, were FDA's augmented drug safety authorities, most specifically the Risk Evaluation and Mitigation Strategy tool. Going into the next round of PDUFA negotiations, a major focus will be on improving the implementation of the REMS program
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials